Genetic testing company 23andMe rises in first trade after Richard Branson SPAC merger

23andMe, a genetic testing start-up that pioneered personalized medicine as a consumer business, trades under ticker "ME" in a deal with Richard Branson's SPAC.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.